Cardlytics Announces Resolution Of SRS Dispute; Cardlytics Agreed To Pay SRS $25M In Cash And Issue SRS 3.6M Shares Of Cardlytics Common Stock
Portfolio Pulse from Benzinga Newsdesk
Cardlytics has settled its dispute with SRS by agreeing to pay $25 million in cash and issuing 3.6 million shares of its common stock to SRS. This resolution concludes the legal conflict between the two entities.
January 29, 2024 | 12:58 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cardlytics' settlement with SRS, involving a $25M cash payment and 3.6M shares issuance, may impact its cash reserves and dilute current shareholders' equity.
The payment of $25M in cash could negatively affect Cardlytics' short-term liquidity and financial stability. The issuance of 3.6M shares will dilute existing shareholders' equity, potentially leading to a negative perception among investors and a decrease in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100